Grants and Contributions:
Title:
Combination treatment development involving orally available small molecule Ribosomal S6 Kinase (RSK) inhibitor PMD-026
Agreement Number:
931368
Agreement Value:
$481,596.00
Agreement Date:
Jul 1, 2019 - Mar 31, 2021
Description:
The Firm has identified a lead compound with novel target to be developed into a potential therapeutic for triple-negative breast cancers (TNBC). This project seeks to develop an advanced formulation for delivery, evaluate the performance of the lead in combination therapies and evaluate the ability of the lead compound to overcome resistance in in vitro models (in anticipation of future in vivo studies).
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Vancouver, British Columbia, CA V6R 1E5
Reference Number:
172-2019-2020-Q2-931368
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
808104087
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The total amended value is 20,000 dollars.
Amendment Date
Mar 22, 2021
Recipient's Legal Name:
Phoenix Molecular Designs Ltd.
Federal Riding Name:
Vancouver Quadra
Federal Riding Number:
59039
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: